Drug actions, reactions and interactions:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Philadelphia [u.a.]
Saunders
2007
|
| Series: | Dermatologic clinics
25,2 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XII S., S. 128-270 Ill. |
| ISBN: | 1416043055 9781416043058 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023044116 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 071211s2007 a||| |||| 00||| engod | ||
| 020 | |a 1416043055 |9 1-4160-4305-5 | ||
| 020 | |a 9781416043058 |9 978-1-4160-4305-8 | ||
| 035 | |a (OCoLC)123114282 | ||
| 035 | |a (DE-599)BVBBV023044116 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 616.5061 |2 22 | |
| 245 | 1 | 0 | |a Drug actions, reactions and interactions |c James Q. Del Rosso, guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2007 | |
| 300 | |a XII S., S. 128-270 |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Dermatologic clinics |v 25,2 | |
| 650 | 4 | |a Dermatologic Agents |x adverse effects | |
| 650 | 4 | |a Dermatologic Agents |x pharmacology | |
| 650 | 4 | |a Dermatology | |
| 650 | 4 | |a Skin Diseases |x drug therapy | |
| 650 | 4 | |a Skin |x Diseases |x Chemotherapy | |
| 700 | 1 | |a DelRosso, James Q. |e Sonstige |4 oth | |
| 830 | 0 | |a Dermatologic clinics |v 25,2 |w (DE-604)BV000004924 |9 25,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016247592&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016247592 | ||
Record in the Search Index
| _version_ | 1804137273922420736 |
|---|---|
| adam_text | DKU. ALTIONS, RKACnONS, AND INTERACTIONS
CONTENTS
Preface xi
James Q. Del Rosso
Status Report on Antibiotic Resistance: Implications for the Dermatologist 127
James Q. Del Rosso and James J. Leyden
In the United States and worldwide, public awareness of the progressive rise in antibio¬
tic resistance has increased among public health officials, the medical community, and
the lay public. The common use of systemic antibiotic therapy in dermatology warrants
a closer look at how prescribing patterns impact on the development of antibiotic resis¬
tant bacteria and outcomes in clinical practice.
Anti Inflammatory Activity of Tetracyclines 133
Guy Webster and James Q. Del Rosso
Tetracyclines are known to exhibit multiple significant anti inflammatory actions. This
article describes the mechanisms of this anti inflammatory activity, such as inhibition
of chemotaxis, granuloma formation, and protease. The article also discusses the effec¬
tiveness of tetracyclines in treating such diseases as acne vulgaris, rosacea, bullous der¬
matoses, granulomatous disease, and livedo vasculitis.
Pharmacologie Modulation of Sebaceous Gland Activity: Mechanisms
and Clinical Applications 137
Shari B. Clarke, Amanda M Nelson, Rosalyn E. George,
and Diane M. Thiboutot
Acne vulgaris is a common skin condition seen by physicians. It primarily affects ado¬
lescents, but can continue into adulthood. A key factor in the pathogenesis of acne is se¬
bum production. Typical therapy includes combinations of topical retinoids and
antimicrobials for mild acne, with the addition of oral antibiotics for moderate to severe
disease. In the most recalcitrant cases or for nodulocystic acne, oral retinoids are indi¬
cated. In women who fail to respond to conventional treatment, hormonal therapy is of¬
ten used adjunctively. Only isotretinoin and hormonal therapy improve acne via their
action on the sebaceous glands. This article focuses on the mechanisms by which these
treatment modalities act on the sebaceous glands and their clinical use in the practice of
medicine.
VOLUME 25 • NUMBER 2 • APRIL 2007 v
Topical Immunomodulation: Modes of Action with Clinical Correlation 147
Neal Bhatia
Many classes and preparations of immunomodulators are available to the clinician, ser¬
ving as stimulatory or inhibitory influences on a variety of disease states. To maximize
their efficacy, it is important for the clinician to take a step back from the usual routine of
treating symptoms and consider the immune processes that took place to create inflam¬
mation, tumors, or responses to infections. From there, after considering the short term
and long term consequences of the treatment, one can match the immune profile of the
disease to the treatment. Most importantly, immunomodulators provide the opportunity
to do what is best for the patient at that time, as well as for control of the future of the
disease, whether it is acute or chronic.
Methicillin Sensitive and Methicillin Resistant Staphylococcus aureus:
Management Principles and Selection of Antibiotic Therapy 157
Dirk M. Elston
Strains of community acquired Methicillin resistant Staphylococcus aureus (CA MRSA)
have emerged as an important group of pathogens. Most infections present as cutaneous
abscess and most of these may respond to drainage alone. Sulfonamide and tetracycline
antibiotics remain valuable agents for most CA MRSA infections, but inducible resis¬
tance to clindamycin is problematic in some areas. Linezolid, and the newer parenteral
antibiotics should be reserved for serious infections.
Advances in Topical and Systemic Antifungals 165
Alexandra Y. Zhang, William L. Camp, and Boni E. Elewski
Topical antifungal agents are generally used for the treatment of superficial fungal infec¬
tions unless the infection is widespread, involves an extensive area, or is resistant to initial
therapy. Systemic antifungals are often reserved for the treatment of onychomycosis, ti¬
nea capitis, superficial and systemic candidiasis, and prophylaxis and treatment of inva¬
sive fungal infections. With the development of resistant fungi strains and the increased
incidence of life threatening invasive fungal infections in immunocompromised patients,
some previously effective traditional antifungal agents are subject to limitations including
multidrug interactions, severe adverse effects, and their fungistatic mechanism of actions.
Several new antifungal agents have demonstrated significant therapeutic benefits and
have broadened clinicians choices in the treatment of superficial and systemic invasive
fungal infections.
Systemic Retinoid Therapy: A Status Report on Optimal Use and Safety
of Long Term Therapy 185
Alpesh Desai, Francisca Kartono, and James Q. Del Rosso
Systemic retinoids are an important component of the dermatology treatment armamen¬
tarium offering unique therapeutic properties, and are widely used to treat a large spec¬
trum of skin disorders. Rational selection of candidates for treatment, knowledge
regarding appropriate and optimal use, awareness of common and uncommon potential
adverse reactions, and proper use of clinical and laboratory monitoring can result in ef¬
fective and safe treatment of several severe skin disorders that impact poorly on the over¬
all health and quality of life of affected patients.
Suggested Guidelines for Patient Monitoring: Hepatic and Hématologie
Toxicity Attributable to Systemic Dermatologie Drugs 195
Stephen E. Wolverton and Kathleen Remlinger
Hepatic and hématologie toxicity are among the most fearful adverse effects that
occasionally occur as a result of systemic drugs in the dermatologist s therapeutic
vi CONTENTS
armamentarium. Drugs of greatest interest concerning hepatic toxicity include metho
trexate, azathioprine, dapsone, and acitretin. Somewhat overlapping are drugs that have
important hématologie toxicities, including methotrexate, azathioprine, dapsone, sulfo
namides, cyclophosphamide, and chlorambucil. Laboratory tests most commonly used
include (1) hepatic monitoring: transaminases (AST/SGOT and ALT/SGPT) and the ul¬
trasound guided liver biopsy, and (2) hématologie monitoring: CBC with diff and plate¬
lets along with occasional use of the reticulocyte count. Important principles and specific
guidelines for monitoring by drug group are highlighted.
Potential Complications Associated with the Use of Biologic Agents
for Psoriasis 207
Joshua A. Zeichner and Mark Lebwohl
The biologic agents are effective drugs to treat psoriasis. They provide physicians with
additional options for patients who cannot tolerate traditional therapies or for whom tra¬
ditional therapies are not sufficient. While these new TNF ot inhibitors and anti—T cell
agents have potential complications, they are generally safe with proper monitoring.
Both physicians and patients should be aware of the risks involved with each medicine
so that the correct drug is chosen to suit each patient.
Drug Reactions Affecting the Nail Unit: Diagnosis and Management 215
Bianca Maria Piraccini and Matilde Iorizzo
Several drugs may be responsible for the development of nail abnormalities, but only a
few classes are consistently associated with nail symptoms. Drug induced nail abnorm¬
alities result from toxicity to the matrix, the nail bed, the periungual tissues, or the digit
blood vessels. Pharmacologie agents that most frequently produce nail abnormalities in¬
clude retinoids, indinavir, and cancer chemotherapeutic agents.
Drug Reactions Affecting Hair: Diagnosis 223
Antonella Tosti and Massimiliano Pazzaglia
Drugs may cause hair loss, stimulate hair growth, or induce changes in the hair shape
and color. Drug induced hair loss is, in most cases, a consequence of a toxic effect of
the drug on the hair matrix. Although a large number of drugs have been occasionally
reported to produce hair loss, the relationship between drug intake and hair loss has
been proven only for a few agents. Type of hair loss (telogen effluvium, anagen efflu¬
vium, or both) depends on the drug, its dosage, and patient s susceptibility. Drug
induced hair loss is usually reversible.
Drug Associated Lymphoma and Pseudolymphoma: Recognition
and Management 233
Joerg Albrecht, Lauren Ann Fine, and Warren Piette
This article discusses ways to recognize and manage lymphomas and pseudolympho
mas associated with drug exposure. Over the last 30 years, the classification of pseudo
lymphomas and lymphomas has undergone significant change, especially following the
application of sophisticated immunostaining and gene rearrangement analysis. The term
cutaneous pseudolymphomas (CPL) is a nonspecific term for a heterogeneous group of
benign reactive T or B cell lymphoproliferative processes that simulate cutaneous lym¬
phomas clinically or histologically. While pseudolymphomas are relatively rare diseases,
their clinical and histological heterogeneity has led to multiple systems of categorization
based on immunological factors, causative agents, presentation, and clinical course.
CONTENTS vii
Recognition and Management of Severe Cutaneous Drug Reactions 245
Sandra R. Knowles and Neil H. Shear
Cutaneous drug reactions are among the most common types of adverse drug reactions.
This article focuses on the recognition and management of severe cutaneous drug erup¬
tions, including the drug hypersensitivity syndrome, serum sickness like reaction, acute
generalized exanthematous pustulosis, Stevens Johnson syndrome, and toxic epidermal
necrolysis. Cutaneous reactions are considered severe when they can result in serious
skin damage or involve multiple organs. Some of these reactions can cause significant
morbidity or death. Each may be confounded by diagnostic difficulties, confusion in as¬
certaining causality, and treatment challenges.
Newly Recognized Cutaneous Drug Eruptions 255
Jeffrey P. Callen
Many new drugs are entering the marketplace and although some cutaneous reactions
might be noted in the preclinical evaluation, some of the reactions, particularly those that
are rare, will not be noted until the drugs enter widespread use. In addition, distinctive
reactions may occur, as is the case with epidermal growth factor receptor inhibitors.
Careful observation and evaluation might result in a better understanding of naturally
occurring skin disease.
Index 263
viii CONTENTS
|
| adam_txt |
DKU. ALTIONS, RKACnONS, AND INTERACTIONS
CONTENTS
Preface xi
James Q. Del Rosso
Status Report on Antibiotic Resistance: Implications for the Dermatologist 127
James Q. Del Rosso and James J. Leyden
In the United States and worldwide, public awareness of the progressive rise in antibio¬
tic resistance has increased among public health officials, the medical community, and
the lay public. The common use of systemic antibiotic therapy in dermatology warrants
a closer look at how prescribing patterns impact on the development of antibiotic resis¬
tant bacteria and outcomes in clinical practice.
Anti Inflammatory Activity of Tetracyclines 133
Guy Webster and James Q. Del Rosso
Tetracyclines are known to exhibit multiple significant anti inflammatory actions. This
article describes the mechanisms of this anti inflammatory activity, such as inhibition
of chemotaxis, granuloma formation, and protease. The article also discusses the effec¬
tiveness of tetracyclines in treating such diseases as acne vulgaris, rosacea, bullous der¬
matoses, granulomatous disease, and livedo vasculitis.
Pharmacologie Modulation of Sebaceous Gland Activity: Mechanisms
and Clinical Applications 137
Shari B. Clarke, Amanda M Nelson, Rosalyn E. George,
and Diane M. Thiboutot
Acne vulgaris is a common skin condition seen by physicians. It primarily affects ado¬
lescents, but can continue into adulthood. A key factor in the pathogenesis of acne is se¬
bum production. Typical therapy includes combinations of topical retinoids and
antimicrobials for mild acne, with the addition of oral antibiotics for moderate to severe
disease. In the most recalcitrant cases or for nodulocystic acne, oral retinoids are indi¬
cated. In women who fail to respond to conventional treatment, hormonal therapy is of¬
ten used adjunctively. Only isotretinoin and hormonal therapy improve acne via their
action on the sebaceous glands. This article focuses on the mechanisms by which these
treatment modalities act on the sebaceous glands and their clinical use in the practice of
medicine.
VOLUME 25 • NUMBER 2 • APRIL 2007 v
Topical Immunomodulation: Modes of Action with Clinical Correlation 147
Neal Bhatia
Many classes and preparations of immunomodulators are available to the clinician, ser¬
ving as stimulatory or inhibitory influences on a variety of disease states. To maximize
their efficacy, it is important for the clinician to take a step back from the usual routine of
treating symptoms and consider the immune processes that took place to create inflam¬
mation, tumors, or responses to infections. From there, after considering the short term
and long term consequences of the treatment, one can match the immune profile of the
disease to the treatment. Most importantly, immunomodulators provide the opportunity
to do what is best for the patient at that time, as well as for control of the future of the
disease, whether it is acute or chronic.
Methicillin Sensitive and Methicillin Resistant Staphylococcus aureus:
Management Principles and Selection of Antibiotic Therapy 157
Dirk M. Elston
Strains of community acquired Methicillin resistant Staphylococcus aureus (CA MRSA)
have emerged as an important group of pathogens. Most infections present as cutaneous
abscess and most of these may respond to drainage alone. Sulfonamide and tetracycline
antibiotics remain valuable agents for most CA MRSA infections, but inducible resis¬
tance to clindamycin is problematic in some areas. Linezolid, and the newer parenteral
antibiotics should be reserved for serious infections.
Advances in Topical and Systemic Antifungals 165
Alexandra Y. Zhang, William L. Camp, and Boni E. Elewski
Topical antifungal agents are generally used for the treatment of superficial fungal infec¬
tions unless the infection is widespread, involves an extensive area, or is resistant to initial
therapy. Systemic antifungals are often reserved for the treatment of onychomycosis, ti¬
nea capitis, superficial and systemic candidiasis, and prophylaxis and treatment of inva¬
sive fungal infections. With the development of resistant fungi strains and the increased
incidence of life threatening invasive fungal infections in immunocompromised patients,
some previously effective traditional antifungal agents are subject to limitations including
multidrug interactions, severe adverse effects, and their fungistatic mechanism of actions.
Several new antifungal agents have demonstrated significant therapeutic benefits and
have broadened clinicians' choices in the treatment of superficial and systemic invasive
fungal infections.
Systemic Retinoid Therapy: A Status Report on Optimal Use and Safety
of Long Term Therapy 185
Alpesh Desai, Francisca Kartono, and James Q. Del Rosso
Systemic retinoids are an important component of the dermatology treatment armamen¬
tarium offering unique therapeutic properties, and are widely used to treat a large spec¬
trum of skin disorders. Rational selection of candidates for treatment, knowledge
regarding appropriate and optimal use, awareness of common and uncommon potential
adverse reactions, and proper use of clinical and laboratory monitoring can result in ef¬
fective and safe treatment of several severe skin disorders that impact poorly on the over¬
all health and quality of life of affected patients.
Suggested Guidelines for Patient Monitoring: Hepatic and Hématologie
Toxicity Attributable to Systemic Dermatologie Drugs 195
Stephen E. Wolverton and Kathleen Remlinger
Hepatic and hématologie toxicity are among the most fearful adverse effects that
occasionally occur as a result of systemic drugs in the dermatologist's therapeutic
vi CONTENTS
armamentarium. Drugs of greatest interest concerning hepatic toxicity include metho
trexate, azathioprine, dapsone, and acitretin. Somewhat overlapping are drugs that have
important hématologie toxicities, including methotrexate, azathioprine, dapsone, sulfo
namides, cyclophosphamide, and chlorambucil. Laboratory tests most commonly used
include (1) hepatic monitoring: transaminases (AST/SGOT and ALT/SGPT) and the ul¬
trasound guided liver biopsy, and (2) hématologie monitoring: CBC with diff and plate¬
lets along with occasional use of the reticulocyte count. Important principles and specific
guidelines for monitoring by drug group are highlighted.
Potential Complications Associated with the Use of Biologic Agents
for Psoriasis 207
Joshua A. Zeichner and Mark Lebwohl
The biologic agents are effective drugs to treat psoriasis. They provide physicians with
additional options for patients who cannot tolerate traditional therapies or for whom tra¬
ditional therapies are not sufficient. While these new TNF ot inhibitors and anti—T cell
agents have potential complications, they are generally safe with proper monitoring.
Both physicians and patients should be aware of the risks involved with each medicine
so that the correct drug is chosen to suit each patient.
Drug Reactions Affecting the Nail Unit: Diagnosis and Management 215
Bianca Maria Piraccini and Matilde Iorizzo
Several drugs may be responsible for the development of nail abnormalities, but only a
few classes are consistently associated with nail symptoms. Drug induced nail abnorm¬
alities result from toxicity to the matrix, the nail bed, the periungual tissues, or the digit
blood vessels. Pharmacologie agents that most frequently produce nail abnormalities in¬
clude retinoids, indinavir, and cancer chemotherapeutic agents.
Drug Reactions Affecting Hair: Diagnosis 223
Antonella Tosti and Massimiliano Pazzaglia
Drugs may cause hair loss, stimulate hair growth, or induce changes in the hair shape
and color. Drug induced hair loss is, in most cases, a consequence of a toxic effect of
the drug on the hair matrix. Although a large number of drugs have been occasionally
reported to produce hair loss, the relationship between drug intake and hair loss has
been proven only for a few agents. Type of hair loss (telogen effluvium, anagen efflu¬
vium, or both) depends on the drug, its dosage, and patient's susceptibility. Drug
induced hair loss is usually reversible.
Drug Associated Lymphoma and Pseudolymphoma: Recognition
and Management 233
Joerg Albrecht, Lauren Ann Fine, and Warren Piette
This article discusses ways to recognize and manage lymphomas and pseudolympho
mas associated with drug exposure. Over the last 30 years, the classification of pseudo
lymphomas and lymphomas has undergone significant change, especially following the
application of sophisticated immunostaining and gene rearrangement analysis. The term
cutaneous pseudolymphomas (CPL) is a nonspecific term for a heterogeneous group of
benign reactive T or B cell lymphoproliferative processes that simulate cutaneous lym¬
phomas clinically or histologically. While pseudolymphomas are relatively rare diseases,
their clinical and histological heterogeneity has led to multiple systems of categorization
based on immunological factors, causative agents, presentation, and clinical course.
CONTENTS vii
Recognition and Management of Severe Cutaneous Drug Reactions 245
Sandra R. Knowles and Neil H. Shear
Cutaneous drug reactions are among the most common types of adverse drug reactions.
This article focuses on the recognition and management of severe cutaneous drug erup¬
tions, including the drug hypersensitivity syndrome, serum sickness like reaction, acute
generalized exanthematous pustulosis, Stevens Johnson syndrome, and toxic epidermal
necrolysis. Cutaneous reactions are considered severe when they can result in serious
skin damage or involve multiple organs. Some of these reactions can cause significant
morbidity or death. Each may be confounded by diagnostic difficulties, confusion in as¬
certaining causality, and treatment challenges.
Newly Recognized Cutaneous Drug Eruptions 255
Jeffrey P. Callen
Many new drugs are entering the marketplace and although some cutaneous reactions
might be noted in the preclinical evaluation, some of the reactions, particularly those that
are rare, will not be noted until the drugs enter widespread use. In addition, distinctive
reactions may occur, as is the case with epidermal growth factor receptor inhibitors.
Careful observation and evaluation might result in a better understanding of "naturally"
occurring skin disease.
Index 263
viii CONTENTS |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV023044116 |
| ctrlnum | (OCoLC)123114282 (DE-599)BVBBV023044116 |
| dewey-full | 616.5061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.5061 |
| dewey-search | 616.5061 |
| dewey-sort | 3616.5061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01366nam a2200361 cb4500</leader><controlfield tag="001">BV023044116</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">071211s2007 a||| |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416043055</subfield><subfield code="9">1-4160-4305-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416043058</subfield><subfield code="9">978-1-4160-4305-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)123114282</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023044116</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.5061</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug actions, reactions and interactions</subfield><subfield code="c">James Q. Del Rosso, guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII S., S. 128-270</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Dermatologic clinics</subfield><subfield code="v">25,2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dermatologic Agents</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dermatologic Agents</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dermatology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Skin Diseases</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Skin</subfield><subfield code="x">Diseases</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">DelRosso, James Q.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Dermatologic clinics</subfield><subfield code="v">25,2</subfield><subfield code="w">(DE-604)BV000004924</subfield><subfield code="9">25,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016247592&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016247592</subfield></datafield></record></collection> |
| id | DE-604.BV023044116 |
| illustrated | Illustrated |
| index_date | 2024-07-02T19:21:45Z |
| indexdate | 2024-07-09T21:09:41Z |
| institution | BVB |
| isbn | 1416043055 9781416043058 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016247592 |
| oclc_num | 123114282 |
| open_access_boolean | |
| physical | XII S., S. 128-270 Ill. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Saunders |
| record_format | marc |
| series | Dermatologic clinics |
| series2 | Dermatologic clinics |
| spelling | Drug actions, reactions and interactions James Q. Del Rosso, guest ed. Philadelphia [u.a.] Saunders 2007 XII S., S. 128-270 Ill. txt rdacontent n rdamedia nc rdacarrier Dermatologic clinics 25,2 Dermatologic Agents adverse effects Dermatologic Agents pharmacology Dermatology Skin Diseases drug therapy Skin Diseases Chemotherapy DelRosso, James Q. Sonstige oth Dermatologic clinics 25,2 (DE-604)BV000004924 25,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016247592&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Drug actions, reactions and interactions Dermatologic clinics Dermatologic Agents adverse effects Dermatologic Agents pharmacology Dermatology Skin Diseases drug therapy Skin Diseases Chemotherapy |
| title | Drug actions, reactions and interactions |
| title_auth | Drug actions, reactions and interactions |
| title_exact_search | Drug actions, reactions and interactions |
| title_exact_search_txtP | Drug actions, reactions and interactions |
| title_full | Drug actions, reactions and interactions James Q. Del Rosso, guest ed. |
| title_fullStr | Drug actions, reactions and interactions James Q. Del Rosso, guest ed. |
| title_full_unstemmed | Drug actions, reactions and interactions James Q. Del Rosso, guest ed. |
| title_short | Drug actions, reactions and interactions |
| title_sort | drug actions reactions and interactions |
| topic | Dermatologic Agents adverse effects Dermatologic Agents pharmacology Dermatology Skin Diseases drug therapy Skin Diseases Chemotherapy |
| topic_facet | Dermatologic Agents adverse effects Dermatologic Agents pharmacology Dermatology Skin Diseases drug therapy Skin Diseases Chemotherapy |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016247592&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000004924 |
| work_keys_str_mv | AT delrossojamesq drugactionsreactionsandinteractions |